- Editorial
407 Views
3 Pages
The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, The Netherlands, from 1 to 3 May 2025, organized by the Kidney Cancer Association (KCA) [...]
Medical Sciences Forum, Volume 39, 2025
IKCSEU 2025 - 7 articles
The 2025 International Kidney Cancer Symposium
Amsterdam, The Netherlands | 1–3 May 2025
Volume Editors:
Axel Bex, The Netherlands Cancer Institute, The Netherlands
Ignacio Durán, Hospital Universitario Marqués de Valdecilla, Spain
Salvatore La Rosa, Kidney Cancer Association, USA
Lisa Pickering, Royal Marsden Hospital, UK
Cover Story: The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, The Netherlands, on 1–3 May 2025, organized by the Kidney Cancer Association (KCA). This annual event serves as the premier European meeting dedicated to kidney cancer research and clinical innovation, fostering collaboration across academia, industry, and advocacy. The symposium showcased cutting-edge research in kidney cancer, highlighting advancements in tumor biology, translational science, real-world evidence, biomarkers, imaging, therapeutics, and quality of care. IKCSEU25 also featured interactive sessions such as Practice Changing Papers, The Woodfire, and Young Investigator Highlights, encouraging multidisciplinary dialogue and translational collaboration.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles (7)
- Proceeding Paper
865 Views
6 Pages
Cabozantinib is a commonly prescribed tyrosine kinase inhibitor for metastatic renal cell carcinoma (mRCC). Dose reductions may be required to manage side effects. Data was collected at University Hospitals Plymouth NHS Trust between 2020 and 2024 to...
- Proceeding Paper
1,216 Views
8 Pages
This single-centre retrospective study evaluated outcomes in 112 patients with metastatic renal cell carcinoma (mRCC) treated with first-line VEGF-TKIs or immune checkpoint inhibitor (IO)-based combinations. The primary objective of this study was to...
- Conference Report
2,806 Views
44 Pages
The 2025 International Kidney Cancer Symposium—Europe (IKCSEU25) was held in Amsterdam, the Netherlands, from 1 to 3 May 2025, organized by the Kidney Cancer Association (KCA). This annual event serves as the premier European meeting dedicated...
- Proceeding Paper
1,062 Views
5 Pages
Since 2010, all Danish departments treating renal cell carcinoma (RCC) have reported to the national quality database, enabling systematic auditing of outcomes. Using the unique Civil Registration Number, data are linked to national registries, ensur...
- Proceeding Paper
1,842 Views
10 Pages
The CABONEXT study is the first multicenter retrospective analysis evaluating subsequent systemic therapies after cabozantinib-based treatment in metastatic renal cell carcinoma (mRCC). This interim analysis includes 77 patients receiving subsequent...
- Proceeding Paper
1,127 Views
5 Pages
Background: Artificial intelligence (AI) has the potential to significantly enhance clinical decision-making in oncology. However, its application in renal cell carcinoma (RCC) remains limited. The ART (Artificial Intelligence in Renal Tumors) projec...
Med. Sci. Forum - ISSN 2673-9992